WORK Medical Tech's January 2025 Report: Board Resignation & New Appointment Insights

Here are the key insights extracted from the provided financial report (Form 6-K) for WORK Medical Technology Group LTD:
- Company Details:
- Name: WORK Medical Technology Group LTD
- Location: Floor 23, No. 2 Tonghuinan Road, Xiaoshan District, Hangzhou City, Zhejiang Province, People's Republic of China.
- Contact: +86-571-82613568
- SEC File Number: 001-42256
- Report Context:
- Type: Report of Foreign Private Issuer
- Filing Period: For the month of January 2025.
- Rule Compliance: Filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
- Board Changes:
- Resignation: Mr. Zhongxuan Li resigned from his position as an independent director and from multiple committees (Audit, Compensation, and Nominating and Corporate Governance) effective December 30, 2024. The resignation was attributed to personal reasons.
- Appointment: Mr. Zhenguo Wu was appointed as an independent director on January 1, 2025. He was also assigned to serve as a member of the Audit, Compensation, and Nominating and Corporate Governance Committees and as the chairperson of the Nominating and Corporate Governance Committee.
- Background of Mr. Wu:
- Legal professional with experience as a lawyer at Watson & Band Law Offices since December 2024.
- Previously served as board secretary and general counsel at Xuhang Holdings Ltd (April 2021 - November 2024).
- Senior vice president of investment banking at Shenwan Hongyuan Securities (October 2015 - February 2021).
- Education: Bachelor’s in English (2010) and Master’s in Law (2013).
- Independence and Transactions:
- Mr. Wu does not have any family relationships with any directors or executive officers of the Company and has not been involved in any transactions with the Company in the past two years that would require disclosure.
- Signature:
- The report was signed by Shuang Wu, Chief Executive Officer of WORK Medical Technology Group LTD, on January 10, 2025.
This report reflects significant governance changes within the company, particularly in its board composition, which may impact its strategic direction and oversight.